Table 1.
Comparison of patient demographics between groups
| Variable | Denosumab (n = 120) | ZA (n = 122) | P – value |
|---|---|---|---|
| Age (years) | 64.9 ± 3.01 | 65.4 ± 3.44 | 0.19*a |
| Menopause age | 53.1 ± 1.82 | 52.9 ± 1.78 | 0.43*a |
| Pathological types, No. | 0.92*b | ||
| Invasive ductal carcinoma | 97 | 98 | |
| Other pathological types | 23 | 24 | |
| Tumor staging | 0.95*c | ||
| I | 53 | 57 | |
| II | 46 | 40 | |
| III | 21 | 25 | |
| BMI (kg/m2) | 24.4 ± 2.34 | 23.9 ± 2.36 | 0.11*a |
| BMD | −2.30 ± 0.21 | −2.33 ± 0.29 | 0.37*a |
| Personal history of fractures | 15/120 | 19/122 | 0.49*b |
| Family history of fractures | 17/120 | 18/122 | 0.90*b |
* No statistically significant values. a Analysed using an Independent-Samples t-test; b Analysed using the Chi-square test; c Analysed using the Mann-Whitney test. ZA: zoledronic acid; SSEs: symptomatic skeletal events; BMI: body mass index; BMD: bone mineral density